Drug intelligence / Profile preview

SAM-005

Development stage: Preclinical
Lead developer: Samsara Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

SAM-005 is a preclinical-stage drug candidate developed by Samsara Therapeutics. It acts as an inhibitor of peripheral myelin protein 22 (PMP22) and is also described as an enzyme replacement therapy. The primary therapeutic focus for SAM-005 is Charcot-Marie-Tooth Disease, Type Ia, a hereditary neuropathy affecting the peripheral nervous system. The drug aims to address nervous system diseases and congenital disorders by targeting PMP22, which plays a key role in myelin sheath maintenance in nerves[1][7].

Beyond the preview

Go deeper on SAM-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAM-005.

Explore the full profile